The influence of MTHFR C677T polymorphism on methotrexate toxicity in pediatric acute lymphoblastic leukemia
Keywords:
acute lymphoblastic leukemia, methotrexate, toxic effects, MTHFR, polymorphismsAbstract
In current protocols for treatment of acute lymphoblastic leukemia in childhood methotrexate (MTX) is one of the crucial cytostatics. The occurrence of MTX toxicity is still а great problem because of the interpatient differences in drug metabolism. These differences may be due to polymorphisms of genes involved in the folate metabolism. The present study was carried out to determine the prevalence of MTHFR C677T polymorphism in children with acute lymphoblastic leukemia (ALL). Also the effect of the genotype on the toxic effects during therapy with high doses of МТХ in 45 patients with ALL treated in accordance with the protocol ALL BFM 95 and ALL BFM 2000 was evaluated. All 45 patients with ALL were genotyped for MTHFR C677T polymorphism. Correlation with the presence of a certain polymorphism and toxic effects of the chemotherapy with high doses of МТХ was made in the Department for hematology and oncology at the University Clinic for children's diseases – Skopje. The control group included 32 healthy patients. In the study group 24 (53.3%) children had a wild type of polymorphism (CC), 15 (33.33%) children were heterozygous (CT) for MTHFR C677T polymorphism, and 6 (13.33%) children were homozygous for the variant type of the polymorphism (ТТ). The correlation of the genotype with МТХ toxicity indicated a statistical significance only for oral mucositis, while for the other toxic effects there was no statistically significant correlation. In our study the results indicated that oral mucositis was statistically significantly more frequently identified in the case of the variant carriers for this polymorphism. For the other toxic effects caused by the therapy with high doses of МТХ no statistically significant correlation with MTHFR C677T polymorphism was identified. This occurrence maybe due to the small number of patients analyzed in this study and the possible protective influence of other genetic polymorphisms included in the folate metabolism, which were not subject to consideration of this study.
Downloads
References
Mí¶ricke A, Reiter A, Zimmermann M et al. Risk - adjusted
therapy of acute lymphoblastic leukemia can decrease
treatment burden and improve survival: treatment
results of 2169 unselected pediatric and adolescent
patients enrolled in the trial ALL-BFM 95. Blood
; 111 (9): 4477-89.
Schmiegelow K. Advances in individual prediction of
methotrexate toxicity: a review. Br J
Haematol 2009; 146:489–503.
Giovannetti E, Ugrasena DG, Supriyadi E et al. Methylenetetrahydrofolate
reductase (MTHFR) C677T and thymidylate
synthase promoter (TSER) polymorphisms in
Indonesian children with and without leukemia. Leuk
Res 2008; 32: 19–24.
Binia A, Contreras A, Canizales-Quinteros S. Geographical
and ethnic distribution of single nucleotide polymorphisms
within genes of the folate/homocysteine
pathway metabolism. Genes Nutr 2014; 9(5):421.
Chiusolo P, Reddiconto G, Casorelli I et al. Preponderance
of methylenetetrahydrofolate reductase C677T
homozygosity among leukemia patients intolerant to
methotrexate. Ann Oncol 2002;13(12):1915-18.
Lopez-Lopez E1, Martin-Guerrero I, Ballesteros J, Garcia-
Orad A. A systematic review and meta-analysis of
MTHFR polymorphisms in methotrexate toxicity prediction
in pediatric acute lymphoblastic leukemia. Pharmacogenomics
J 2013;13(6):498-506.
Schrappe M, Reiter A, Zimmerman M et al.: Long term
results of four consecutive trials in childhood ALL performed
by ALL-BFM study group from1981-1995. Leukemia
;14 (12):2205-22.
Fukushima H, Fukushima T, Sakai A et al., et al. Polymorphisms
of MTHFR Associated with Higher Relapse/
Death Ratio and Delayed Weekly MTX Administration
in Pediatric Lymphoid Malignancies. Leuk Res Treatment
; Article ID 238528,
http://dx.doi.org/10.1155/2013/238528.
Yang L, Hu X, Xu L. Impact of methylenetetrahydrofolate
reductase (MTHFR) polymorphisms on methotrexate-
induced toxicities in acute lymphoblastic leukemia:
a meta-analysis. Tumor Biology 2012; 33(5):
-54.
Shimasaki N, Mori T, Samejima H et al. Effects of methylenetetrahydrofolate
reductase and reduced folate
carrier 1 polymorphisms on high-dose methotrexateinduced
toxicities in children with acute lymphoblastic
leukemia or lymphoma. J Pediatr Hematol Oncol
;28(2):64-8.
Seidemann K, Book M, Zimmermann M et al. MTHFR
(C"”>T) polymorphism is not relevant for prognosis
or therapy-associated toxicity in pediatric NHL: results
from 484 patients of multicenter trial NHL-BFM
Ann Hematol 2006;85: 291-300.
Faganel Kotnik B, Grabnar I, Bohanec Grabar P,
Dolžan V, Jazbec J. Association of genetic polymorphism
in the folate metabolic pathway with methotrexate
pharmacokinetics and toxicity in childhood
acute lymphoblastic leukaemia and malignant
lymphoma. Eur J Clin Pharmacology 2011;
(10):993-1006.
Krajinovic M, Lamothe S, Labuda D et al. Role of
MTHFR genetic polymorphisms in the susceptibility to
childhood acute lymphoblastic leukemia. Blood 2004;
(1): 252-7
Evans WE, Crews K R and Pui C-H. A Health-Care System
Perspective on Implementing Genomic Medicine:
Pediatric Acute Lymphoblastic Leukemia as a Paradigm.
Clin Pharmacol Ther 2013;94(2):224-9.
Costea I , Moghrabi A , Laverdiere C, Graziani
A, Krajinovic M. Folate Cycle Gene Variants And Chemotherapy
Toxicity In Pediatric Patients With Acute
Lymphoblastic Leukemia. Haematologica
; 91(8): 1113-16.
Downloads
Published
How to Cite
Issue
Section
License
All wrights are reserved.


